Abstract
CDX2 is a widely used immunohistochemical marker for intestinal differentiation in neoplasms. In the Nordic Immunohistochemical Quality Control external quality assessment scheme, only 45% of the laboratories participating in the CDX2 challenge in 2009 produced sufficient staining. A major cause of insufficient staining results appeared to be less successful primary antibody (Ab) clones. To evaluate the Ab performance in a standardized way, a comparative study was carried out.
| Original language | English |
|---|---|
| Journal | Applied Immunohistochemistry & Molecular Morphology |
| Volume | 21 |
| Issue number | 1 |
| Pages (from-to) | 64-72 |
| Number of pages | 9 |
| ISSN | 1541-2016 |
| DOIs | |
| Publication status | Published - Jan 2013 |
Keywords
- Adenocarcinoma
- Antibodies, Monoclonal
- Carcinoma, Squamous Cell
- Cell Transformation, Neoplastic
- Denmark
- Diagnosis, Differential
- Homeodomain Proteins
- Humans
- Immunohistochemistry
- Intestinal Neoplasms
- Lung Neoplasms
- Quality Assurance, Health Care
- Quality Control
- Quality Improvement
- Sensitivity and Specificity
- Tissue Array Analysis
- Tumor Markers, Biological